D'Haens G, Danese S, Panaccione R, Rubin DT, et al. Deucravacitinib in Patients With Inflammatory Bowel Disease: 12-Week Efficacy and Safety Results From Three Randomized Phase 2 Studies in Crohn's Disease and Ulcerative Colitis. J Crohns Colitis 2025 May 13:jjaf080. doi: 10.1093.
PMID: 40355364